- Report
- December 2024
- 125 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- November 2024
- 202 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- December 2024
- 102 Pages
Asia Pacific
From €5656EUR$5,950USD£4,752GBP
- Report
- October 2024
- 135 Pages
Asia Pacific
From €3803EUR$4,000USD£3,195GBP
- Report
- March 2025
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2024
- 200 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- December 2024
- 80 Pages
United States
From €4706EUR$4,950USD£3,953GBP
- Report
- November 2023
- 149 Pages
Asia Pacific
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2023
- 189 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Drug Pipelines
- July 2022
- 60 Pages
Global
From €2139EUR$2,250USD£1,797GBP
- Report
- November 2023
- 157 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- January 2023
- 296 Pages
Global
From €3422EUR$3,600USD£2,875GBP

The Multi Cancer Early Detection market is a subset of the Diagnostics industry that focuses on the early detection of multiple types of cancer. This market is driven by the need to detect cancer at its earliest stages, when it is most treatable. Diagnostic tests used in this market include blood tests, imaging tests, and biopsies. These tests are used to detect cancer markers, such as proteins, hormones, and genetic mutations.
The Multi Cancer Early Detection market is highly competitive, with many companies offering innovative products and services. Companies in this market include Grail, Freenome, Guardant Health, and Tempus. These companies are focused on developing tests that can detect multiple types of cancer with high accuracy and sensitivity. Additionally, these companies are working to make their tests more accessible and affordable for patients. Show Less Read more